PERSPECTA

News from every angle

← Back to headlines

Truist Lowers Price Target for Viridian Therapeutics

Truist Securities has adjusted its price target for Viridian Therapeutics (VRDN) from $40 to $36, indicating a revised outlook on the company's stock performance.

20 Apr, 21:32 — 20 Apr, 21:32
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual122d ago

Truist Cuts PT on Viridian Therapeutics (VRDN) to $36 From $40

Read full article →

Related Stories

Bank of America's Sell Signal Flashes Red Amid Bullish Investor Sentiment

2h ago

Crude Oil Futures Rise Amid US Economic Measure Threats

22h ago

Leggett & Platt Shareholders Approve Somnigroup Merger

1d ago

Andersen Announces Pricing of Class A Secondary Offering at $44 Per Share

1d ago